A5036685729- Cancer, Hypoxia, and Metabolism
- Adrenal and Paraganglionic Tumors
- Ubiquitin and proteasome pathways
- Glioma Diagnosis and Treatment
- Nuclear Receptors and Signaling
- Hormonal Regulation and Hypertension
- DNA Repair Mechanisms
- Genetics and Neurodevelopmental Disorders
- Mitochondrial Function and Pathology
- DNA and Nucleic Acid Chemistry
- RNA Interference and Gene Delivery
- ATP Synthase and ATPases Research
- 14-3-3 protein interactions
- Polyomavirus and related diseases
- Receptor Mechanisms and Signaling
- Nerve injury and regeneration
- Histone Deacetylase Inhibitors Research
- Cancer therapeutics and mechanisms
- Acute Myeloid Leukemia Research
- Renal Diseases and Glomerulopathies
- Neurotransmitter Receptor Influence on Behavior
- Acute Lymphoblastic Leukemia research
- Cholesterol and Lipid Metabolism
- Analytical Methods in Pharmaceuticals
- RNA regulation and disease
Jikei University School of Medicine
2025
National Cancer Institute
2024
National Institutes of Health
2024
Center for Cancer Research
2024
Fukuoka University
2007
University of Tsukuba
2007
University of Tokyo Hospital
2000
The University of Tokyo
1999
In previous studies, it has been demonstrated that ciliary neurotrophic factor (CNTF) a potent survival effect on various populations of neurons in culture, particular, isolated from chick ciliary, dorsal root sensory, and sympathetic ganglia (Barbin et al., 1984). After recent investigations CNTF prevents the degeneration motoneurons newborn rats after axonal lesion (Sendtner 1990), question arose as to whether also embryonic at developmental stage where physiological cell death occurs. To...
Abstract Current treatment options for metastatic adrenocortical carcinoma (ACC) have limited efficacy, despite the common use of mitotane and cytotoxic agents. This study aimed to identify novel therapeutic ACC. An extensive drug screen was conducted compounds with potential activity against ACC cell lines. We further investigated mechanism action identified compound, TAK-243, its synergistic effects current therapeutics, efficacy in models including patient-derived organoids mouse...
Ataxia telangiectasia and Rad3-related (ATR) checkpoint kinase inhibitors are in clinical trials. Here we explored the molecular pharmacology therapeutic combination strategies of oral ATR inhibitor M1774 (Tuvusertib) with DNA-damaging agents (DDA). As single agent, suppressed cancer cell viability at nanomolar concentrations, showing greater activity than ceralasertib berzosertib, but less potency gartisertib elimusertib small lung H146, H82, DMS114 lines. also efficiently blocked...
<p>Supplement Table 1</p>
<p>Supplement Figure 1 related to 2</p>
<p>Supplement Table 2, related to Figure 5 and 6.</p>
<p>Supplement Figure 2 related to 4</p>
<p>Supplement Figure 4</p>
<p>Supplement Figure 3 related to 8</p>
Lipoprotein glomerulopathy (LPG) is considered a type of renal lipidosis, characterized by the presence lipoprotein thrombi in markedly dilated capillary lumina affected glomeruli [1]. LPG rare disease; approximately 65 cases have been reported to date [2]. Patients with exhibit proteinuria and progressive dysfunction. In most patients, levels intermediate-density lipoproteins are elevated, resembling III hyperlipoproteinaemia; moreover, apolipoprotein E (ApoE) also elevated. Recent genetic...
<p>Cytotoxicity of TAK-243 on ACC cell lines. <b>A,</b> Concentration–response curve and IC<sub>50</sub> values in lines SW-13. Cell viability after 72 hours under the indicated drug concentrations was measured by CellTiter-Glo assay. <b>B,</b> Expression ABC transporters (MDR-1, BCRP) SLFN11 Proteins were extracted from each line expression SLFN11, MDR-1, BCRP evaluated Western blotting. <b>C,</b> Effects DNA synthesis cycle. CU-ACC1,...
<div>Abstract<p>Current treatment options for metastatic adrenocortical carcinoma (ACC) have limited efficacy, despite the common use of mitotane and cytotoxic agents. This study aimed to identify novel therapeutic ACC. An extensive drug screen was conducted compounds with potential activity against ACC cell lines. We further investigated mechanism action identified compound, TAK-243, its synergistic effects current therapeutics, efficacy in models including patient-derived...
<p>NCATS screening identifies TAK-243 as one of the most potent drugs against ACC cell lines. <b>A,</b> CU-ACC1, CU-ACC2, and NCI-H295R lines were screened with NCATS MIPE v5.0 (MIPE 5.0) library approved investigational (<i>n</i> = 2,480). Drugs Z-AUC values less than −1.5 good-quality dose–response curves selected. The number effective in three is shown Venn diagram (left). 21 commonly their mechanism action tabulated. <b>B,</b> arranged order for...
<p>Expression of ABCB1/SLFN11 and BCL2/BAX in clinical cancer samples.</p>
<p>Immunostaining of CU-ACC1 xenograft tissue. Body weight changes in mice.</p>
<p>Synergistic effect of TAK-243 on Navitoclax. Analysis synergistic effects using the MTT assay.</p>
<p>Synergistic effect of TAK-243 on Navitoclax. Analysis synergistic effects using the MTT assay.</p>
<p>High UBA1 expression, and hyperactivation of the E1 E2 enzymes ubiquitin pathways in ACC.</p>